Tumor necrosis factor α (TNFα) blockers are proven as potential suppressing agents on rheumatoid arthritis. Not only showing significant effects in clinical treatment, yet they are also known as top largest selling among the biological agents. However, several systemic side effects are shown after treatments with TNFα blockers which are related to infection and cancer. In order to reduce and overcome the side effects, a targeted delivery is then requested. Synovial membrane is considered as a promising delivery target because TNFα is highly accumulated therein. The current article reviewed a number of strategies that might be applied in the synovial membrane targeting for TNFα blocker.
Key words: rheumatoid arthritis, tumor necrosis factor α blocker, synovium, targeting delivery
|
